Long‐term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer-Reference-Cited by-同舟云学术

Long‐term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer

Published:2021-06-22 Issue:15 Volume:10 Page:5163-5174
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Wijetunga N. Ari¹^ORCID,dos Anjos Carlos H.²,Zhi W. Iris²^ORCID,Robson Mark²,Tsai C. Jillian¹³,Yamada Yoshiya¹³,Dover Laura¹³,Gillespie Erin F.¹³,Xu Amy J.¹³,Yang Jonathan T.¹³

Affiliation:

1. Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York NY USA

2. Department of Medicine Division of Solid Tumor Oncology Breast Medicine Service Memorial Sloan Kettering Cancer Center New York NY USA

3. Precision Radiation for Oligometastatic and Metastatic Disease (PROMISE) Program Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York NY USA

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4068

Reference39 articles.

1. Breast Cancer Metastasis: Challenges and Opportunities

2. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States

3. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer